Thermo Fisher Scientific Inc. (TMO) KPIs and segments
Close on Nov 17, 2026Market cap $254.47BP/E 36.2Yield 0.25%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Thermo Fisher Scientific · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Thermo Fisher Scientific: 40 chỉ số vận hành, trong đó có Remaining Performance Obligations / Backlog, Current Contract Liabilities và Current Contract Assets, Net, lấy từ 164 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q4 2027 | Q3 2027 | Q2 2027 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Laboratory Products and Biopharma Services($M) | 6,863 | 6,693 | 6,036 | 6,379 | 5,970 | 5,995 | 5,640 | ||||||
Life Sciences Solutions($M) | 2,719 | 2,815 | 2,636 | 2,946 | 2,588 | 2,499 | 2,341 | ||||||
Analytical Instruments($M) | 2,002 | 1,847 | 1,716 | 2,215 | 1,893 | 1,728 | 1,718 | ||||||
Specialty Diagnostics($M) | 1,098 | 1,205 | 1,142 | 1,220 | 1,174 | 1,134 | 1,148 | ||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)15 | |||||||||||||
Product revenues($M) | 6,753 | 6,823 | 6,277 | 7,246 | 6,489 | 6,249 | 5,980 | ||||||
Services($M) | 5,384 | 5,171 | 4,728 | 4,969 | 4,633 | 4,605 | 4,384 | ||||||
Consumables($M) | 4,870 | 5,073 | 4,722 | 5,026 | 4,679 | 4,606 | 4,354 | ||||||
Instruments($M) | 1,883 | 1,750 | 1,555 | 2,221 | 1,811 | 1,644 | 1,626 | ||||||
North America($M) | 6,266 | 6,149 | 5,705 | 6,109 | 5,689 | 5,722 | 5,513 | ||||||
Europe($M) | 3,201 | 3,311 | 2,957 | 3,367 | 3,005 | 2,830 | 2,624 | ||||||
Asia-Pacific($M) | 2,240 | 2,104 | 1,970 | 2,277 | 2,013 | 1,920 | 1,891 | ||||||
Other regions($M) | 430 | 430 | 372 | 462 | 415 | 383 | 337 | ||||||
Laboratory Products and Biopharma Services($M) | 256 | 62 | 33 | 8 | 39 | 56 | 45 | ||||||
Life Sciences Solutions($M) | 2 | 13 | 9 | 22 | 78 | 11 | 42 | ||||||
Analytical Instruments($M) | 1 | 17 | 4 | 13 | 54 | 10 | 4 | ||||||
Specialty Diagnostics($M) | -60 | 3 | 5 | 0 | 3 | 2 | |||||||
Laboratory Products and Biopharma Services($M) | 1,067 | 936 | 778 | 925 | 868 | 825 | 731 | ||||||
Life Sciences Solutions($M) | 1,022 | 1,041 | 954 | 1,046 | 968 | 919 | 834 | ||||||
Analytical Instruments($M) | 538 | 424 | 355 | 583 | 429 | 325 | 399 | ||||||
Specialty Diagnostics($M) | 341 | 334 | 313 | 324 | 321 | 306 | 304 | ||||||
Life Sciences Solutions($M) | 1,706 | 1,735 | 1,632 | 1,758 | 1,627 | 1,574 | 1,486 | ||||||
Laboratory Products and Biopharma Services($M) | 1,683 | 1,543 | 1,279 | 1,455 | 1,362 | 1,328 | 1,230 | ||||||
Analytical Instruments($M) | 1,049 | 922 | 840 | 1,076 | 919 | 826 | 883 | ||||||
Specialty Diagnostics($M) | 511 | 506 | 485 | 503 | 492 | 494 | 469 | ||||||
Product revenues($M) | 3,415 | 3,361 | 3,016 | 3,524 | 3,170 | 3,010 | 2,855 | ||||||
Services($M) | 1,716 | 1,521 | 1,414 | 1,487 | 1,413 | 1,398 | 1,380 | ||||||
Specialty Diagnostics($M) | -21 | -24 | -35 | -36 | -34 | -25 | -33 | ||||||
Analytical Instruments($M) | -25 | -17 | -36 | -49 | -18 | -13 | -44 | ||||||
Life Sciences Solutions($M) | -85 | -59 | -20 | -51 | -32 | -25 | -43 | ||||||
Laboratory Products and Biopharma Services($M) | -272 | -260 | -259 | -298 | -297 | -206 | -205 | ||||||
Laboratory Products and Biopharma Services($M) | 7,414 | 7,152 | 6,921 | 6,485 | 6,763 | 6,711 | 6,467 | ||||||
Life Sciences Solutions($M) | 3,597 | 3,508 | 3,490 | 3,446 | 3,552 | 3,142 | 3,018 | ||||||
Analytical Instruments($M) | 3,259 | 3,187 | 3,104 | 3,170 | 3,189 | 3,070 | 2,986 | ||||||
Specialty Diagnostics($M) | 1,129 | 1,323 | 1,332 | 1,323 | 1,307 | 1,295 | 1,298 | ||||||
Remaining performance obligations (RPO)($M) | 29,870 | 29,700 | 29,410 | 26,460 | 25,040 | 24,540 | |||||||
Remaining Performance Obligations / Backlog($M)2 | 29,700 | 29,410 | 27,920 | 26,460 | 25,040 | 24,540 | |||||||
Reported RPO / Backlog ($B)($M) | 29.7 | 29.4 | 27.9 | 26.5 | 25.0 | 24.5 | |||||||
Portion of RPO Expected to Be Recognized as Revenue within Next 12 Months(%) | 52.0% | 52.0% | 52.0% | 53.0% | 54.0% | 54.0% | |||||||
Current Contract Liabilities (Deferred Revenue / Customer Advances)($M)2 | 2,918 | 2,928 | 2,710 | 2,852 | 2,805 | 2,866 | |||||||
Noncurrent Contract Liabilities($M) | 1,043 | 1,034 | 1,183 | 1,159 | 1,122 | 1,127 | |||||||
Quarterly Revenue Recognized from Beginning-of-Year Contract Liability Balances (Q1–Q3)($M) | 710 | 1,290 | 410 | 730 | 1,360 | ||||||||
Current Contract Assets, Net($M)1 | 1,688 | 1,684 | 1,666 | 1,620 | 1,441 | 1,366 | |||||||
Noncurrent Contract Assets, Net($M) | 0 | 1 | 1 | 1 | 1 | 4 | |||||||
Consolidated Organic Revenue Growth(%)3 | 6.0% | 5.0% | 1.0% | 3.0% | 3.0% | 2.0% | 1.0% | ||||||
Reported Revenue Growth(%) | 9.0% | 10.0% | 6.0% | 7.0% | 5.0% | 3.0% | 0.0% | ||||||
Impact of Acquisitions, Net of Divestitures(%) | 3.0% | 5.0% | 3.0% | 2.0% | 1.0% | 0.0% | 0.0% | ||||||
Impact of Currency Translation(%) | 0.0% | 1.0% | 2.0% | 2.0% | 1.0% | 1.0% | -1.0% | ||||||
Organic Revenue Growth — Life Sciences Solutions(%)3 | 1.0% | 3.0% | 1.0% | 4.0% | 5.0% | 4.0% | 2.0% | ||||||
Reported Revenue Growth — Life Sciences Solutions(%) | 5.0% | 13.0% | 13.0% | 13.0% | 8.0% | 6.0% | 2.0% | ||||||
Impact of Acquisitions — Life Sciences Solutions(%) | 4.0% | 9.0% | 9.0% | 8.0% | 3.0% | 1.0% | 2.0% | ||||||
Impact of Currency Translation — Life Sciences Solutions(%) | 0.0% | 1.0% | 3.0% | 2.0% | 1.0% | 1.0% | -1.0% | ||||||
Organic Revenue Growth — Analytical Instruments(%)3 | 6.0% | 7.0% | -2.0% | 0.0% | 4.0% | -4.0% | 3.0% | ||||||
Reported Revenue Growth — Analytical Instruments(%) | 6.0% | 7.0% | 0.0% | 1.0% | 5.0% | -3.0% | 2.0% | ||||||
Impact of Acquisitions — Analytical Instruments(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||||
Impact of Currency Translation — Analytical Instruments(%) | 0.0% | 0.0% | 2.0% | 2.0% | 1.0% | 1.0% | -1.0% | ||||||
Organic Revenue Growth — Specialty Diagnostics(%)3 | 0.0% | 5.0% | -3.0% | 3.0% | 2.0% | 0.0% | 4.0% | ||||||
Reported Revenue Growth — Specialty Diagnostics(%) | -6.0% | 6.0% | -1.0% | 5.0% | 4.0% | 2.0% | 3.0% | ||||||
Impact of Acquisitions — Specialty Diagnostics(%) | -6.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||||
Impact of Currency Translation — Specialty Diagnostics(%) | 0.0% | 1.0% | 3.0% | 2.0% | 2.0% | 1.0% | -1.0% | ||||||
Organic Revenue Growth — Laboratory Products & Biopharma Services(%)3 | 10.0% | 5.0% | 4.0% | 5.0% | 3.0% | 3.0% | -1.0% | ||||||
Reported Revenue Growth — Laboratory Products & Biopharma Services(%) | 15.0% | 12.0% | 7.0% | 7.0% | 4.0% | 4.0% | -1.0% | ||||||
Impact of Acquisitions — Laboratory Products & Biopharma Services(%) | 6.0% | 6.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||||||
Impact of Currency Translation — Laboratory Products & Biopharma Services(%) | 0.0% | 1.0% | 2.0% | 2.0% | 1.0% | 1.0% | -1.0% | ||||||
R&D as % of Manufacturing Revenue(%) | 6.7% | 6.9% | 6.9% | ||||||||||
Fiscal Calendar Selling Days Delta(ngày) | -4 | 0 | 0 | 4 | 1 | 0 | 0 | -1 | 1 | 0 | 0 | -2 | |
Consumables Revenue($M)2 | 5,073 | 4,722 | 5,026 | 4,679 | 4,606 | 4,354 | |||||||
Cost of Product Revenues($M) | 3,462 | 3,261 | 3,722 | 3,319 | 3,239 | 3,125 | |||||||
Cost of Service Revenues($M) | 3,650 | 3,314 | 3,482 | 3,220 | 3,207 | 3,004 | |||||||
Life Sciences Solutions Segment (Total Segment Revenue)($M)4 | 2,719 | 2,815 | 2,636 | 2,946 | 2,588 | 2,499 | 2,341 | ||||||
Biosciences (Molecular Biology Reagents, Cell Culture & Protein)($M) | 1,060 | 981 | 1,078 | 1,023 | 1,075 | 993 | |||||||
Genetic Sciences (Gene Sequencing, qPCR & Genetic Analysis)($M) | 703 | 655 | 794 | 720 | 679 | 677 | |||||||
BioProduction (Single-Use Bioproduction Systems & Consumables)($M) | 941 | 893 | 966 | 817 | 745 | 671 | |||||||
Other / Intersegment Eliminations — Life Sciences Solutions Segment($M) | 112 | 107 | 109 | 28 | 0 | 0 | |||||||
Analytical Instruments Segment (Total Segment Revenue)($M)3 | 2,002 | 1,847 | 1,716 | 2,215 | 1,893 | 1,728 | 1,718 | ||||||
Chromatography and Mass Spectrometry (Chromatography & Mass Spectrometry)($M) | 821 | 798 | 962 | 841 | 784 | 773 | |||||||
Electron Microscopy / Materials & Structural Analysis (Cryo-EM Electron Microscopy & Semiconductors)($M) | 707 | 633 | 914 | 732 | 652 | 659 | |||||||
Chemical Analysis (Industrial, Environmental & Pharmaceutical Chemical Analysis)($M) | 318 | 285 | 339 | 320 | 292 | 286 | |||||||
Specialty Diagnostics Segment (Total Segment Revenue)($M)5 | 1,098 | 1,205 | 1,142 | 1,220 | 1,174 | 1,134 | 1,148 | ||||||
Clinical Diagnostics (Clinical Diagnostics & Specialty Testing)($M) | 290 | 271 | 293 | 283 | 276 | 263 | |||||||
ImmunoDiagnostics (Phadia Allergy & Autoimmune Diagnostics)($M) | 248 | 230 | 231 | 230 | 234 | 217 | |||||||
Microbiology (Clinical Microbiology & Culture Media)($M) | 166 | 160 | 172 | 162 | 159 | 152 | |||||||
Transplant Diagnostics (One Lambda HLA Transplant Diagnostics)($M) | 134 | 121 | 130 | 125 | 124 | 113 | |||||||
Healthcare Market Channel (Fisher Healthcare Hospital Diagnostics Distribution Channel)($M) | 442 | 430 | 463 | 444 | 407 | 474 | |||||||
Laboratory Products and Biopharma Services Segment (Total Segment Revenue)($M)4 | 6,863 | 6,693 | 6,036 | 6,379 | 5,970 | 5,995 | 5,640 | ||||||
Pharma Services — Patheon CDMO (Contract Pharmaceutical Manufacturing & Sterile Fill-Finish)($M) | 1,893 | 1,741 | 2,019 | 1,722 | 1,794 | 1,607 | |||||||
Clinical Research — PPD CRO (Global Clinical Research & Trial Services)($M) | 2,396 | 2,128 | 2,001 | 2,019 | 1,955 | 1,939 | |||||||
Research and Safety Market Channel — Fisher Scientific (Laboratory Distribution Channel)($M) | 2,036 | 1,827 | 1,969 | 1,861 | 1,883 | 1,727 | |||||||
Laboratory Products (Basic Equipment, Ultra-Low Temperature Freezers & Laboratory Plastics)($M) | 608 | 569 | 631 | 594 | 601 | 582 | |||||||
North America Revenue($M) | 6,149 | 5,705 | 6,109 | 5,689 | 5,722 | 5,513 | |||||||
Segment Income — Life Sciences Solutions($M)10 | 1,022 | 1,041 | 954 | 1,046 | 968 | 919 | 834 | ||||||
Segment Income Margin — Life Sciences Solutions(%) | 37.6% | 37.0% | 36.2% | 35.5% | 37.4% | 36.8% | 35.6% | ||||||
Margin Expansion (percentage points) — Life Sciences Solutions(%) | 0.2% | 0.2% | 0.6% | -1.1% | 2.0% | 0.1% | -1.2% | ||||||
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Life Sciences Solutions($M) | 2,355 | 2,219 | 2,518 | 2,194 | 2,115 | 1,954 | |||||||
Intersegment Revenues — Note 11 — Life Sciences Solutions($M) | 460 | 417 | 428 | 394 | 385 | 387 | |||||||
Segment Cost of Revenues — ASU 2023-07 — Life Sciences Solutions($M) | 1,080 | 1,004 | 1,187 | 961 | 925 | 855 | |||||||
Segment SG&A — ASU 2023-07 — Life Sciences Solutions($M) | 500 | 496 | 506 | 470 | 467 | 468 | |||||||
Segment R&D Expense — ASU 2023-07 — Life Sciences Solutions($M) | 140 | 131 | 145 | 136 | 135 | 139 | |||||||
Other Segment Items — Life Sciences Solutions($M) | 54 | 50 | 63 | 53 | 54 | 45 | |||||||
Segment Purchases of PP&E — Life Sciences Solutions($M) | 59 | 20 | 51 | 32 | 25 | 43 | |||||||
Segment Depreciation — Life Sciences Solutions($M) | 69 | 70 | 74 | 62 | 56 | 59 | |||||||
Segment Income — Analytical Instruments($M)10 | 538 | 424 | 355 | 583 | 429 | 325 | 399 | ||||||
Segment Income Margin — Analytical Instruments(%) | 26.9% | 23.0% | 20.7% | 26.3% | 22.6% | 18.8% | 23.2% | ||||||
Margin Expansion (percentage points) — Analytical Instruments(%) | 4.3% | 4.2% | -2.5% | -4.2% | -2.3% | -5.8% | -0.5% | ||||||
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Analytical Instruments($M) | 1,799 | 1,667 | 2,160 | 1,847 | 1,669 | 1,677 | |||||||
Intersegment Revenues — Note 11 — Analytical Instruments($M) | 47 | 49 | 56 | 46 | 58 | 41 | |||||||
Segment Cost of Revenues — ASU 2023-07 — Analytical Instruments($M) | 925 | 876 | 1,137 | 975 | 902 | 835 | |||||||
Segment SG&A — ASU 2023-07 — Analytical Instruments($M) | 315 | 313 | 305 | 307 | 317 | 313 | |||||||
Segment R&D Expense — ASU 2023-07 — Analytical Instruments($M) | 140 | 139 | 147 | 144 | 145 | 137 | |||||||
Other Segment Items — Analytical Instruments($M) | 43 | 34 | 43 | 39 | 39 | 33 | |||||||
Segment Purchases of PP&E — Analytical Instruments($M) | 17 | 36 | 49 | 18 | 13 | 44 | |||||||
Segment Depreciation — Analytical Instruments($M) | 27 | 26 | 28 | 26 | 26 | 24 | |||||||
Segment Income — Specialty Diagnostics($M)9 | 341 | 334 | 313 | 324 | 321 | 306 | 304 | ||||||
Segment Income Margin — Specialty Diagnostics(%) | 31.0% | 27.7% | 27.4% | 26.6% | 27.4% | 27.0% | 26.5% | ||||||
Margin Expansion (percentage points) — Specialty Diagnostics(%) | 3.6% | 0.7% | 0.9% | 3.0% | 1.5% | 0.3% | 0.0% | ||||||
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Specialty Diagnostics($M) | 1,188 | 1,124 | 1,202 | 1,154 | 1,118 | 1,130 | |||||||
Intersegment Revenues — Note 11 — Specialty Diagnostics($M) | 17 | 18 | 18 | 20 | 16 | 18 | |||||||
Segment Cost of Revenues — ASU 2023-07 — Specialty Diagnostics($M) | 699 | 657 | 717 | 682 | 640 | 679 | |||||||
Segment SG&A — ASU 2023-07 — Specialty Diagnostics($M) | 177 | 177 | 179 | 175 | 183 | 171 | |||||||
Segment R&D Expense — ASU 2023-07 — Specialty Diagnostics($M) | 45 | 44 | 44 | 42 | 47 | 45 | |||||||
Segment Purchases of PP&E — Specialty Diagnostics($M) | 24 | 35 | 36 | 34 | 25 | 33 | |||||||
Segment Depreciation — Specialty Diagnostics($M) | 20 | 24 | 23 | 23 | 23 | 22 | |||||||
Segment Income — Laboratory Products & Biopharma Services($M)9 | 1,067 | 936 | 778 | 925 | 868 | 825 | 731 | ||||||
Segment Income Margin — Laboratory Products & Biopharma Services(%) | 15.5% | 14.0% | 12.9% | 14.5% | 14.5% | 13.8% | 13.0% | ||||||
Margin Expansion (percentage points) — Laboratory Products & Biopharma Services(%) | 1.0% | 0.2% | -0.1% | 0.5% | 1.0% | 0.9% | 0.0% | ||||||
Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Laboratory Products & Biopharma Services($M) | 6,652 | 5,995 | 6,335 | 5,927 | 5,953 | 5,603 | |||||||
Intersegment Revenues — Note 11 — Laboratory Products & Biopharma Services($M) | 41 | 41 | 45 | 43 | 42 | 37 | |||||||
Segment Cost of Revenues — ASU 2023-07 — Laboratory Products & Biopharma Services($M) | 5,150 | 4,757 | 4,881 | 4,622 | 4,667 | 4,410 | |||||||
Segment SG&A — ASU 2023-07 — Laboratory Products & Biopharma Services($M) | 677 | 597 | 619 | 582 | 595 | 588 | |||||||
Segment R&D Expense — ASU 2023-07 — Laboratory Products & Biopharma Services($M) | 27 | 15 | 15 | 14 | 14 | 13 | |||||||
Segment Purchases of PP&E — Laboratory Products & Biopharma Services($M) | 260 | 259 | 298 | 297 | 206 | 205 | |||||||
Segment Depreciation — Laboratory Products & Biopharma Services($M) | 216 | 186 | 165 | 115 | 152 | 172 | |||||||
Total Segment Income (4 Segments)($M)4 | 2,735 | 2,399 | 2,878 | 2,587 | 2,375 | 2,269 | |||||||
Total Segment AR + Inventory (4 Segments)($M) | 113,174 | 113,281 | 110,343 | 103,020 | 101,230 | 99,041 | |||||||
Unallocated Corporate Assets: Cash, PP&E, Goodwill, Intangibles($M) | 98,003 | 98,434 | 95,919 | 88,209 | 87,013 | 85,272 | |||||||
Unallocated Corporate CapEx($M) | 90 | 28 | 31 | 23 | 25 | 36 | |||||||
Unallocated Corporate Depreciation($M) | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
Total Restructuring & Other Costs — Note 14($M)1 | 98 | 49 | 46 | 135 | 82 | 98 | |||||||
Accrued Restructuring Costs Balance($M) | 72 | 65 | 70 | 85 | 74 | 59 | |||||||
Adjusted Operating Income($M)14 | 2,968 | 2,735 | 2,399 | 2,878 | 2,587 | 2,375 | 2,269 | ||||||
Adjusted Operating Margin(%) | 24.5% | 22.8% | 21.8% | 23.6% | 23.3% | 21.9% | 21.9% | ||||||
GAAP Operating Margin(%) | 18.6% | 17.4% | 16.9% | 18.5% | 17.4% | 16.9% | 16.6% | ||||||
Adjusted Gross Margin $M($M) | 5,200 | 4,970 | 4,490 | 5,104 | 4,662 | 4,487 | 4,319 | ||||||
Adjusted Gross Margin %(%) | 42.8% | 41.4% | 40.8% | 41.8% | 41.9% | 41.3% | 41.7% | ||||||
GAAP Gross Margin %(%) | 42.3% | 40.7% | 40.3% | 41.0% | 41.2% | 40.6% | 40.9% | ||||||
Amortization of Intangibles in COGS($M) | 61 | 61 | 47 | 61 | 68 | 68 | 73 | ||||||
Adjusted SG&A Expense $M($M) | 1,883 | 1,872 | 1,755 | 1,870 | 1,729 | 1,759 | 1,707 | ||||||
Adjusted SG&A % of Revenue(%) | 15.5% | 15.6% | 16.0% | 15.3% | 15.5% | 16.2% | 16.5% | ||||||
GAAP R&D % of Total Revenue(%) | 2.9% | 3.0% | 3.1% | 2.9% | 3.1% | 3.2% | 3.3% | ||||||
Adjusted EBITDA($M) | 3,276 | 3,066 | 2,705 | 3,169 | 2,813 | 2,631 | 2,545 | ||||||
Adjusted Effective Tax Rate(%) | 11.6% | 11.6% | 10.5% | 10.5% | 11.0% | 10.0% | 10.0% | ||||||
Adjusted Net Income($M) | 2,477 | 2,241 | 2,027 | 2,475 | 2,190 | 2,026 | 1,950 | ||||||
Adjusted Diluted EPS($) | 6.68 | 6.03 | 5.44 | 6.57 | 5.79 | 5.36 | 5.15 | ||||||
Free Cash Flow = Operating Cash Flow − Net CapEx($M) | 2,115 | 1,678 | 825 | 3,018 | 1,840 | 1,105 | 373 | ||||||
Adjusted ROIC — Trailing 5-Quarter Average(%)8 | 11.0% | 10.9% | 11.0% | 11.3% | 11.3% | 11.3% | 11.4% | ||||||
TTM Adjusted NOPAT (12-Month)($M) | 9,662 | 9,336 | 9,056 | 8,963 | |||||||||
Trailing 5-Quarter Average Invested Capital($M) | 87,609 | 85,420 | 82,669 | 79,313 | |||||||||
Adjusted ROE(%) | 18.3% | 18.0% | 17.7% | 17.7% | 17.7% | 17.5% | 17.9% | ||||||
Trailing 5-Quarter Average Equity($M) | 52,767 | 51,908 | 51,243 | 50,765 | |||||||||
Total Debt / TTM EBITDA(×) | 3.60 | 3.80 | 4.00 | 3.70 | 3.50 | 3.40 | 3.30 | ||||||
Total Debt / Adjusted TTM EBITDA(×) | 3.40 | 3.60 | 3.80 | 3.50 | 3.20 | 3.20 | 3.20 | ||||||
Net Debt / TTM EBITDA(×) | 3.10 | 3.50 | 3.70 | 2.80 | 3.10 | 2.80 | 2.70 | ||||||
Net Debt / Adjusted TTM EBITDA(×) | 2.90 | 3.30 | 3.50 | 2.60 | 2.90 | 2.70 | 2.60 | ||||||
Share Repurchases Total Spend($M)3 | 0 | 1,000 | 3,000 | 0 | 2,000 | ||||||||
Shares Repurchased (million shares)(M) | 0 | 2.10 | 4.90 | 2.10 | 0 | 3.60 | |||||||
Remaining Share Repurchase Authorization($M) | 1,000 | 1,000 | 2,000 | 5,000 | 1,000 | 1,000 | |||||||
Dividends Paid per Share($) | 0.47 | 0.47 | 0.43 | 0.43 | 0.39 | ||||||||
Total Inventories — Note 2($M)3 | 5,627 | 5,496 | 5,425 | 5,745 | 5,559 | 5,224 | |||||||
Raw Materials($M) | 1,991 | 1,925 | 1,877 | 1,984 | 1,947 | 1,862 | |||||||
Work in Process($M) | 952 | 942 | 889 | 990 | 947 | 874 | |||||||
Finished Goods($M) | 2,683 | 2,629 | 2,659 | 2,771 | 2,665 | 2,488 | |||||||
Property, Plant & Equipment, net — Note 2($M) | 10,755 | 10,658 | 10,565 | 10,177 | 9,635 | 9,331 | |||||||
FDA 510(k) Medical Device/Diagnostic Clearances Granted to Thermo Fisher (openFDA)3 | 1 | 1 | 0 | 2 | 3 | 6 | 4 | ||||||
Total FDA 510(k) Clearances for U.S. Medical Device & Diagnostic Industry (U.S. Industry Total) | 855 | 923 | 756 | 806 | 797 | 886 | 736 | ||||||
FDA High-Risk Device PMA & Supplement Approvals Granted to Thermo Fisher (openFDA) | 3 | 1 | 2 | 9 | 3 | 0 | 0 | ||||||
Total U.S. Industry FDA PMA & Supplements Approvals (U.S. Industry Total) | 565 | 608 | 567 | 525 | 585 | 588 | 524 | ||||||
Thermo Fisher Medical Device Recalls Recorded in FDA CDRH System (openFDA Device Recalls)6 | 1 | 6 | 1 | 2 | 4 | 1 | 4 | ||||||
FDA Recall Enforcement Reports (Drugs + Devices + Biologics) for Thermo Fisher (openFDA Enforcement) | 2 | 5 | 1 | 2 | 4 | 1 | 4 | ||||||
Total MAUDE MDR Device Adverse Event Reports for Thermo Fisher (openFDA MAUDE) | 15 | 13 | 18 | 18 | 12 | 16 | 30 | ||||||
Device Malfunction MDRs — Thermo Fisher | 3 | 3 | 3 | 3 | 0 | 1 | 15 | ||||||
Injury MDRs — Thermo Fisher | 11 | 10 | 13 | 14 | 11 | 12 | 13 | ||||||
Death MDRs — Thermo Fisher | 1 | 0 | 2 | 1 | 1 | 3 | 2 | ||||||
Total U.S. Industry MAUDE Device Adverse Event Reports (U.S. Industry Total MDRs) | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | ||||||
U.S. Producer Price Index (PPI): Laboratory Analytical Instruments (NAICS 334516 — BLS/FRED)(×)5 | 203.60 | 203.60 | 202.00 | 198.70 | 195.80 | 195.90 | 194.50 | ||||||
U.S. Producer Price Index (PPI): In-Vitro Diagnostic Substances & Biologicals (NAICS 325413 — BLS/FRED)(×) | 300.60 | 300.60 | 303.90 | 300.50 | 299.80 | 297.70 | 291.70 | ||||||
U.S. Producer Price Index (PPI): Pharmaceutical Preparation Manufacturing (NAICS 325412 — BLS/FRED)(×) | 929.20 | 926.20 | 926.00 | 919.30 | 918.70 | 914.90 | 916.50 | ||||||
U.S. Producer Price Index (PPI): Medical Instruments & Equipment (NAICS 339112 — BLS/FRED)(×) | 163.60 | 163.40 | 161.80 | 159.80 | 159.40 | 157.10 | 156.90 | ||||||
U.S. Producer Price Index (PPI): Electromedical Equipment (NAICS 334510 — BLS/FRED)(×) | 92.80 | 92.10 | 92.00 | 91.60 | 90.90 | 90.30 | 90.10 | ||||||
U.S. Census QSS Hospitals Revenue ($M)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | |||||||
Consolidated Revenue($M)12 | 12,137 | 11,994 | 11,005 | 12,215 | 11,122 | 10,855 | 10,364 | ||||||
Gross Profit — Financial Statements & IR Reconciliation($M) | 5,131 | 4,881 | 4,430 | 5,011 | 4,584 | 4,408 | 4,235 | ||||||
SG&A($M) | 1,863 | 2,333 | 2,181 | 2,352 | 2,162 | 2,140 | 2,078 | ||||||
R&D Expense($M) | 348 | 364 | 336 | 356 | 346 | 352 | 342 | ||||||
Restructuring & Merger Charges($M) | 38 | 34 | 36 | 62 | 56 | 43 | |||||||
Operating Income($M) | 2,263 | 2,087 | 1,863 | 2,255 | 1,941 | 1,834 | 1,716 | ||||||
Interest Expense($M) | 401 | 354 | 365 | 347 | 404 | 303 | |||||||
Interest Income($M) | 207 | 233 | 258 | 234 | 297 | 203 | |||||||
Pretax Income($M) | 1,924 | 1,734 | 2,153 | 1,826 | 1,709 | 1,620 | |||||||
Income Tax Provision($M) | 167 | 70 | 153 | 207 | 92 | 95 | |||||||
GAAP Net Income($M) | 1,721 | 1,736 | 1,651 | 1,964 | 1,616 | 1,617 | 1,507 | ||||||
EPS pha loãng GAAP (GAAP Diluted EPS — DB & 8-K)($) | 4.64 | 4.68 | 4.43 | 5.21 | 4.27 | 4.28 | 3.98 | ||||||
Dividends per Share($) | 0.47 | 0.47 | 0.43 | 0.43 | 0.43 | 0.43 | |||||||
Total Assets($M)11 | 113,174 | 113,281 | 110,343 | 103,020 | 101,230 | 99,041 | |||||||
Cash & Equivalents($M) | 4,064 | 3,254 | 9,852 | 1,982 | 4,603 | 4,172 | |||||||
Accounts Receivable, Net($M) | 9,451 | 9,204 | 8,900 | 8,911 | 8,594 | 8,455 | |||||||
Inventories, Net($M) | 5,627 | 5,496 | 5,425 | 5,745 | 5,559 | 5,224 | |||||||
PP&E, Net($M) | 10,755 | 10,658 | 10,565 | 10,177 | 9,635 | 9,331 | |||||||
Goodwill($M) | 54,832 | 55,187 | 49,362 | 49,287 | 47,249 | 46,493 | |||||||
Intangible Assets, Net($M) | 18,606 | 19,146 | 15,838 | 16,242 | 15,148 | 15,323 | |||||||
Accounts Payable($M) | 3,268 | 3,344 | 3,622 | 3,120 | 2,980 | 3,049 | |||||||
Current Deferred Revenue($M) | 2,918 | 2,928 | 2,710 | 2,852 | 2,805 | 2,866 | |||||||
Current Debt (Due Within 1 Year)($M) | 3,368 | 3,090 | 3,533 | 3,823 | 2,214 | 2,819 | |||||||
Long-Term Debt($M) | 39,181 | 40,071 | 35,852 | 31,857 | 33,015 | 31,370 | |||||||
Shareholders' Equity($M) | 52,679 | 51,934 | 53,407 | 51,018 | 50,512 | 49,390 | |||||||
Operating Cash Flow($M)5 | 2,125 | 1,192 | 3,457 | 2,239 | 1,399 | 723 | |||||||
Capital Expenditures($M) | 450 | 376 | 465 | 404 | 294 | 362 | |||||||
Stock-Based Compensation($M) | 82 | 83 | 84 | 70 | 81 | 75 | |||||||
Acquisitions, Net of Cash Acquired($M) | -0 | 8,872 | -0 | 4,037 | -0 | -0 | |||||||
Share Repurchases($M) | 1,000 | 3,000 | 37 | 963 | -0 | 2,000 | |||||||
Dividends Paid($M) | 175 | 162 | 162 | 163 | 162 | 149 | |||||||
10 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Remaining Performance Obligations / Backlog from Note 2 of the 10-K/10-Q ($27.92 billion at the end of FY2025, $25.73 billion as of Q2 2026, with the % expected to be recognized as revenue over the next 12 months) and customer contract asset / liability balances.
- Permissible quarterly derivations: Flow metrics reported only for Q1–Q3 and cumulative 6M/9M on Form 10-Q along with full-year figures on Form 10-K (15 sub-segments in Note 6, Consumables/Instruments/Services breakdown, 4 geographic regions, segment Cost of Goods Sold/SG&A/R&D expenses under ASU 2023-07 Note 11, restructuring charges in Note 14, and cash flows) have fourth-quarter figures derived using the formula Q4 = Full Year (10-K) − 9 Months (10-Q) from the same filing version.
- Consolidated vs. standalone: Not applicable to TMO because the company prepares consolidated financial statements under US GAAP and does not issue standalone parent company financial statements (Schedule I is not required since restricted assets of subsidiaries are < 25% of consolidated assets).
- Reporting cycle Q3 2026 vs. Q2 2026: The Q3 2026 8-K filing, Q3 2026 IR financial reconciliation package, Q3 2026 earnings call, openFDA, and BLS/FRED reflect data through FY2026Q3 (2026-09); detailed footnote disclosures available only in Form 10-Q (Note 2 RPO, Note 6 15 sub-segments, Note 11 ASU 2023-07 segment expenses) reflect data through FY2026Q2 because the Q3 2026 10-Q was not yet filed at the time of the Q3 2026 8-K earnings release.
Không hiện vì thiếu các kỳ gần đây (11)
- Total Restructuring & Other Costs — Note 14 › Restructuring Costs — Specialty Diagnostics
- Total Restructuring & Other Costs — Note 14 › Restructuring Costs — Corporate
- Consolidated Revenue › Cost of Revenue (discontinued after FY2018 when Product/Service separated)
- Consolidated Revenue › Diluted Shares
- Operating Cash Flow › Depreciation & Amortization
- China Revenue (no longer reported separately in Note 11 after Q2 2023)
- Germany Revenue (no longer reported separately after FY2016)
- UK Revenue (discontinued as a separate disclosure after FY2016)
- Japan Revenue (discontinued as a separate disclosure after FY2016)
- Adjusted ROIC — Trailing 5-Quarter Average › GAAP-based ROIC
- Share Repurchases Total Spend › Average Price Paid per Share
Dữ liệu cập nhật 2026-10-29.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
1. Remaining Performance Obligations / Backlog & Customer Contracts
2. Organic Growth Bridge, End Markets & Selling Calendar
- Consolidated Organic Revenue Growth (%)15 kỳ
- Organic Revenue Growth — Life Sciences Solutions (%)15 kỳ
- Organic Revenue Growth — Analytical Instruments (%)16 kỳ
- Organic Revenue Growth — Specialty Diagnostics (%)15 kỳ
- Organic Revenue Growth — Laboratory Products & Biopharma Services (%)15 kỳ
- End-Market Revenue Mix: Pharma & Biotech (%)2 kỳ
- R&D as % of Manufacturing Revenue (%)9 kỳ
- Fiscal Calendar Selling Days Delta (ngày)16 kỳ
3. Revenue Disaggregation across 15 Operating Businesses, Economic Characteristics & Geographic Regions (Note 6)
- Consumables Revenue ($M)28 kỳ
- Life Sciences Solutions Segment (Total Segment Revenue) ($M)19 kỳ
- Analytical Instruments Segment (Total Segment Revenue) ($M)19 kỳ
- Specialty Diagnostics Segment (Total Segment Revenue) ($M)19 kỳ
- Laboratory Products and Biopharma Services Segment (Total Segment Revenue) ($M)19 kỳ
- North America Revenue ($M)28 kỳ
4. Cost Breakdown (Cost of Revenues, SG&A, R&D), Operating Assets & Restructuring by Segment (ASU 2023-07)
- Segment Income — Life Sciences Solutions ($M)19 kỳ
- Segment Income — Analytical Instruments ($M)19 kỳ
- Segment Income — Specialty Diagnostics ($M)19 kỳ
- Segment Income — Laboratory Products & Biopharma Services ($M)19 kỳ
- Total Segment Income (4 Segments) ($M)10 kỳ
- Total Restructuring & Other Costs — Note 14 ($M)6 kỳ
5. Non-GAAP Profitability, ROIC / ROE, Financial Leverage, Inventory / PP&E Structure & Capital Allocation
6. Global Workforce, Quality & FDA/ISO Compliance, Occupational Safety, Supply Chain & Environment
7. Industry & Independent Regulatory Agency Data (openFDA Clearances / Recalls / MAUDE & BLS / Census)
8. Financial Statement & Cash Flow Context from Financial Statements
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Thermo Fisher Scientific
- Q3 2026 Reconciliation of Financial Information ↗
- SEC Form 10-Q (10q_2026Q2, filed 2026-07-31) ↗
- SEC Form 10-K (10k_2025, filed 2026-02-26) ↗
- 2025–2026 CSR Report — Data Summary (Foleon) ↗
- openFDA 510(k) Premarket Notifications — Thermo Fisher & Subsidiaries ↗
- openFDA Medical Device Recalls — Thermo Fisher & Subsidiaries ↗
- BLS / FRED Producer Price Index: Analytical Laboratory Instrument Manufacturing (PCU334516334516) ↗
- SEC 10-K (filed 2026-02-26, acc 0000097745-26-000018) ↗
- SEC 10-Q (filed 2026-07-31, acc 0000097745-26-000144) ↗
- 2026 J.P. Morgan Healthcare Conference Presentation (2026-01-13) ↗
- Q3 2026 Earnings Call Transcript (2026-10-22) ↗
- Q4 2025 Earnings Call Transcript (2026-01-29) ↗
See a number that looks wrong?